Buy, sell, hold: 5 stock that analysts are watching out

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Moneycontrol Bureau Here are five stocks that analysts are watching out post September quarter results.HPCL CLSA retains outperform call with target price at Rs 480 per share.  It says rebound in Asian benchmark gross refining margin (GRM) and Indian oil demand should aid earnings. Credit Suisse maintains outperform rating with target unchanged at Rs 477 per share as Q2 was hurt by inventory losses.

GAIL CLSA retains sell call as valuations  are not attractive. It has increased FY17/18 EPS by 13 percent. It raised target to Rs 405 from Rs 360 per share. Morgan Stanley is underweight call with target at Rs 328 per share as it does not t see any material changes to FY17 estimates Credit Suisse maintains underperform call with target unchanged at Rs 310 per share as transmission segment robust and  polymer ramp-up promising.   CIMB has a reduce call with target of Rs 330 per share as transmission volumes improved but additional upside unlikely. It has lowered interest rates to benefit private banks & mortgage providers. Bank of America Merrill Lynch has an underperform rating with target at Rs 380 per share as transmission segment outperforms. Deutsche Bank has a sell call on the stock with target at Rs 380 per share as gas volumes grow, but US LNG contract risks ahead.

Jefferies maintains hold rating due to concerns over US LNG contracts but target is raised to Rs 450 from Rs 382 per share. It says lower domestic gas prices should also help LPG profits in the near-term and raised FY17/FY18 EPS estimates.

Reliance CommunicationCLSA retains sell call with target cut  to Rs 36 from Rs 43 per share as Q2 results were operationally weak. It says CDMA migration complete but risk of further subscriber loss remains and margin may remain under pressure.

HDFC Bank CLSA retains buy call with a target of  Rs 1530 per share as demonetisation is a long-term plus, but smooth transition is key. It expects an earnings CAGR of 23 percent over FY16-19.

Aurobindo PharmaGoldman Sachs has  a buy call on the stock with  target at Rs 1000 per share as  launch mix & margin progress set up  favourable outlook.